Myriad Genetics Inc (MYGN)
18.65
-0.27
(-1.43%)
USD |
NASDAQ |
Apr 17, 16:00
18.65
0.00 (0.00%)
After-Hours: 20:00
Myriad Genetics Enterprise Value: 1.598B for April 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 16, 2024 | 1.598B |
| April 15, 2024 | 1.621B |
| April 12, 2024 | 1.655B |
| April 11, 2024 | 1.740B |
| April 10, 2024 | 1.718B |
| April 09, 2024 | 1.774B |
| April 08, 2024 | 1.726B |
| April 05, 2024 | 1.718B |
| April 04, 2024 | 1.715B |
| April 03, 2024 | 1.722B |
| April 02, 2024 | 1.695B |
| April 01, 2024 | 1.825B |
| March 28, 2024 | 1.814B |
| March 27, 2024 | 1.821B |
| March 26, 2024 | 1.829B |
| March 25, 2024 | 1.873B |
| March 22, 2024 | 1.896B |
| March 21, 2024 | 1.902B |
| March 20, 2024 | 1.896B |
| March 19, 2024 | 1.839B |
| March 18, 2024 | 1.842B |
| March 15, 2024 | 1.799B |
| March 14, 2024 | 1.814B |
| March 13, 2024 | 1.833B |
| March 12, 2024 | 1.836B |
| Date | Value |
|---|---|
| March 11, 2024 | 1.927B |
| March 08, 2024 | 1.930B |
| March 07, 2024 | 1.948B |
| March 06, 2024 | 1.959B |
| March 05, 2024 | 1.896B |
| March 04, 2024 | 1.872B |
| March 01, 2024 | 1.891B |
| February 29, 2024 | 1.779B |
| February 28, 2024 | 1.840B |
| February 27, 2024 | 2.010B |
| February 26, 2024 | 1.958B |
| February 23, 2024 | 1.940B |
| February 22, 2024 | 1.974B |
| February 21, 2024 | 1.957B |
| February 20, 2024 | 2.010B |
| February 16, 2024 | 1.988B |
| February 15, 2024 | 2.018B |
| February 14, 2024 | 2.002B |
| February 13, 2024 | 1.813B |
| February 12, 2024 | 1.970B |
| February 09, 2024 | 1.875B |
| February 08, 2024 | 1.886B |
| February 07, 2024 | 1.874B |
| February 06, 2024 | 1.917B |
| February 05, 2024 | 1.862B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
812.70M
Minimum
Mar 18 2020
3.557B
Maximum
Aug 02 2019
1.716B
Average
1.720B
Median
May 31 2023
Enterprise Value Benchmarks
| Stryker Corp | 138.34B |
| Haemonetics Corp | 4.951B |
| Perspective Therapeutics Inc | 849.38M |
| Electromed Inc | 113.48M |
| Xtant Medical Holdings Inc | 118.85M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.20M |
| Revenue (Quarterly) | 196.60M |
| Total Expenses (Quarterly) | 115.20M |
| EPS Diluted (Quarterly) | -0.36 |
| Gross Profit Margin (Quarterly) | 68.67% |
| Profit Margin (Quarterly) | -15.87% |
| Earnings Yield | -17.16% |
| Normalized Earnings Yield | -10.40 |